Diagnosing Cancer

Through Tumor Related Microbial Biomarkers

Micronoma liquid biopsy technology interrogates the microbial signal to detect and predict cancer with clinical-grade accuracy.

Connect-Cool-Companies-2020

Our Focus

Saving patient lives with a minimally-invasive, cancer screening test.

Latest News

Micronoma Establishes Scientific Advisory Board

International oncology, microbiome and drug discovery expertise synergize to guide unique early cancer detection startup SAN DIEGO, Dec. 9, 2020 /PRNewswire/ -- Micronoma, the first cancer detection biotech company that uses signals from the tumor-related microbiome...

Micronoma Expands Executive Team and Operations

Innovative early cancer detection company establishes headquarters and adds three key executive positions San Diego, Calif. (November 5, 2020). Micronoma, an early-stage cancer detection biotech company seeking to develop and commercialize a minimally-invasive, unique...

Humans and Microbes

Humans and microbes co-exist in a mutual beneficial relationship in our bodies. Microbes can be found naturally not only in our stools, but also in our mouths, tissues and even our blood.

The Microbiome

The microbiome is the community of all the microbes—bacteria, fungi, protozoa and viruses—that live on and inside the human body.

Microbes and Cancer

Microbes are now known to be found in human tissues, including cancer tissues. Micronoma is going a step further and looking at microbial signatures that would be predictive of a tumor in circulating blood.

Micronoma can detect and distinguish microbes in blood and predict if a patient is cancer free or presenting a specific cancer type.

BLOOD DRAW
Minimally-invasive blood
draw to collect samples
for testing.

MICROBIOME
Pioneering microbiome
research, discovery, and
applications.

NEXT GEN SEQUENCING
Using genomic sequencing to
accurately distinguish
microbial signatures.

BIOINFORMATICS
Using computational
pipelines to decipher and
interpret data.

PROBLEM

18

MILLION
New cancer cases
worldwide each year

9

MILLION
Cancer deaths each year,
most preventable with
early detection

$6.1

BILLION
Global liquid biopsy market
forecast for 2023*

*BCC Research

 Better Approach to Liquid Biopsy

A liquid biopsy is a test done on a sample of blood to look for circulating tumor cells (CTC) or DNA that is shed from the tumor. Liquid biopsies may help find cancer at an early stage.

___________

However, CTCs and ctDNA are scarce, fragile, and heterogenous, which means they are difficult to detect and may be missed. Additionally, they may not be cancer-specific, as various cancers can share many types of alterations.

___________

Traditional liquid biopsies focus on all tumor DNA in the blood to identify the small mutation markers linked to the cancer. Present at often less than 0.1%, ensuring the capture of these rare biomarkers is a difficult task. At Micronoma, we focus on the microbial DNA. With noise and complexity removed, established microbial signatures are enriched and more evident.

OncobiotaTM

OncobiotaTM is an approach to identify cancer tissue associated microbes and distinguish the presence and type of cancer.

Leadership

Sandrine Miller-Montgomery,
Pharm. D., Ph.D.

Co-Founder, Board Member, President and Chief Executive Officer

Greg Poore

Co-Founder,  Board Member, Chief Analytic Officer, Oncobiota™ Co-Inventor

Rob Knight, Ph.D.

Co-Founder and Scientific Advisory Board, Oncobiota™ Co-Inventor

Eddie Adams, Ph.D.

Chief Scientific Officer

Darryl Garrison

Chief Operating Officer

Magda Marquet, Ph.D.

Chairman of the Board; Co-Founder, Ajinomoto Althea & AltheaDx

Scientific Advisory Board

Martin J. Blaser, M.D.

Chairman, Professor of Medicine and Pathology and Director of the Center for Advanced Biotechnology and Medicine, and holds the Henry Rutgers Chair of the Human Microbiome at Rutgers University.

Leena Das-Young, Pharm. D.

C-suite executive for biopharma in oncology, infectious disease, liquid biopsy, and product development in complex disease and precision medicine settings, including executive roles at both Pfizer and Guardant Health.

Ravid Straussman, M.D., Ph.D.

Principal Investigator at the Weizmann Institute where his research is focused on understanding the roles of the tumor microenvironment and the tumor microbiome on resistance to cytotoxic, targeted, and immune-mediated anti-cancer therapies.

Micronoma
6342 Ferris Square
San Diego, CA 92121
info@micronoma.com

Contact Us

If you have questions or would like to learn more, please email us at info@micronoma.com or contact us at media.relations@micronoma.com,

biocom